Drugs / ADRX-0706
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06036121 | Sep 2023 → Sep 2025 overdue | cervical cancer, triple-negative breast carcinoma, urothelial carcinoma | Adcentrx Therapeutics | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2025-05-06 | Adcentrx Therapeutics | Regulatory Adcentrx Therapeutics Granted Fast Track Designation for ADRX-0706 Nectin-4 ADC for the Treatment of Advanced Cervical Cancer adcentrx.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead program, ADRX-0706, for the treatment of patients with locally advanced or metastatic squamous cell cervical cancer. |
| 2025-04-23 | Adcentrx Therapeutics | Results Adcentrx Therapeutics to Present First Clinical Data for ADRX-0706 Nectin-4 ADC at ASCO 2025 adcentrx.com ↗ |
| 2024-05-06 | Adcentrx Therapeutics | Regulatory Adcentrx Therapeutics Announces China NMPA Grants IND Clearance for ADRX-0706, a Novel Nectin-4 ADC for the Treatment of Advanced Solid Tumors adcentrx.com ↗ |
| 2024-04-01 | Adcentrx Therapeutics | Results Adcentrx Therapeutics to Present Preclinical Data for Nectin-4 ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024 adcentrx.com ↗
The preclinical data presentations show improved therapeutic window of ADRX-0706, enhanced bystander effect and improved payload delivery to Nectin-4 expressing tumors while minimizing exposure to normal tissues. |
| 2023-07-17 | Adcentrx Therapeutics | Regulatory Adcentrx Therapeutics Announces FDA Clearance of Investigational New Drug Application for ADRX-0706, a Novel ADC Targeting Nectin-4 for the Treatment of Advanced Solid Tumors adcentrx.com ↗
Adcentrx Therapeutics (“Adcentrx”), a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application of ADRX-0706 for the treatment of select advanced solid tumors. |
All press releases naming this drug 7 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADRX-0706 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06036121 ↗ |
| Modality | Other / unclassified | “Antibody drug conjugate targeting Nectin-4” NCT06036121 ↗ |